“Advancements in Laser Therapies and Minimally Invasive Surgical Techniques”
- A significant and accelerating trend in the global primary angle-closure glaucoma (PACG) market is the increasing adoption of advanced laser therapies and minimally invasive glaucoma surgeries (MIGS), aimed at improving safety, efficacy, and long-term intraocular pressure control. These developments are transforming the clinical management landscape for PACG across both developed and emerging regions
- For instance, laser peripheral iridotomy (LPI) is now a standard first-line treatment, with advanced devices from Iridex and Ellex offering more precise energy delivery and reduced complications. Similarly, MIGS devices such as iStent and Hydrus Microstent are gaining traction for their ability to provide effective drainage with minimal trauma
- Innovations in imaging, including anterior segment optical coherence tomography (AS-OCT), are enabling ophthalmologists to better assess angle structure and plan targeted interventions. Furthermore, combining cataract surgery with goniosynechialysis or stenting is proving particularly effective in managing chronic PACG
- The integration of advanced diagnostic and surgical solutions allows for earlier intervention, faster recovery, and reduced dependence on long-term medication. These technologies are increasingly adopted by eye care centers seeking to deliver high-standard, patient-centric treatment
- This trend toward safer, less invasive, and more precise treatments is reshaping expectations for glaucoma care. As a result, companies are focusing on developing compact laser platforms and improved micro-implants tailored for PACG patients
- The demand for streamlined, minimally invasive glaucoma care is rising steadily across both hospital and ambulatory settings, as healthcare providers and patients asuch as seek better outcomes, fewer complications, and enhanced quality of life
